ValiRx to present at key Cancer Conference

Shares in life science company ValiRx rose on Tuesday morning after the AIM-listed company announced that it would be presenting at the American Association for Cancer Research Conference this year.

Shares in life science company ValiRx rose on Tuesday morning after the AIM-listed company announced that it would be presenting at the American Association for Cancer Research Conference this year.

The conference, which was attended by approximately 17,000 delegates last year, is seen as a key event designed to showcase and bring together developments in major areas of cancer research.

The company said that its participation in the upcoming conference on April 6th represented the first time it had been selected to give a presentation at the event.

The company further reported that a "number of key milestones" had been achieved, in particular for VAL 201, the company's anti-cancer therapeutic which has been in the clinical development phase for prostate cancer since the summer of 2012.

Having been in dialogue with regulatory authorities, ValiRx said it was finalising the associated regulatory activities for the first-in-man studies - commonly termed phase 1a and Ib/IIa studies. The phase 1a studies are expected to complete in 2013, subject to suitable patient access.

The company's other key compound - VAL 101 - a development programme for down regulation of rebellious genes, was described as being at an "advanced pre-clinical stage".

Satu Vainikka, Chief Executive Officer of ValiRx, said: "Our technical and commercial progress over the past year has been pleasing and we are well set for the future as we look to further establish ourselves at the forefront of personalised oncology development."

ValiRx's share price was up 4.04% to 0.52p at 08:37 on Tuesday.

MF

Recommended

The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into
2 Mar 2023
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
27 Feb 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023

Most Popular

Five changes to state pensions coming next month
Pensions

Five changes to state pensions coming next month

There are several changes happening to state pensions in April. We explain what’s happening.
22 Mar 2023
When will interest rates go up?
UK Economy

When will interest rates go up?

The Bank of England raised rates to 4.25%, its 11th consecutive increase. Does the base rate have further to go?
23 Mar 2023
Will energy prices go down in 2023?
Personal finance

Will energy prices go down in 2023?

Ofgem’s price cap is now predicted to fall below £2,000, based on average typical use, from July, for the first time since 2022. We have all the detai…
21 Mar 2023